DAXXIFY

Peak

botulinum toxin type a

BLAINTRAMUSCULAR, SUBCUTANEOUSINJECTABLE
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
14

Mechanism of Action

Acetylcholine Release Inhibitors

Pharmacologic Class:

Acetylcholine Release Inhibitor

Clinical Trials (5)

NCT06293300Phase 2Recruiting

Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)

Started Sep 2024
50 enrolled
Traumatic Brain Injury
NCT06068855Phase 3Completed

A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants

Started Oct 2023
249 enrolled
Masseter Muscle Prominence
NCT04673240N/AUnknown

CLINICAL EFFECT OF BOTULINUM TOXIN TYPE A IN TREATMENT OF SPASTICITY

Started Mar 2019
70 enrolled
SpasticityBrain InjuriesSpinal Cord Injuries+1 more
NCT03779841Phase 2Completed

Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)

Started Mar 2019
323 enrolled
Post-Operative Atrial Fibrillation
NCT02390206N/ACompleted

Study on the Use of Botulinum Toxin Type A in the Treatment of Chronic Post-stroke Spastic Patients

Started Jun 2015
239 enrolled
Spasticity